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The data presented in this article supports the rat brain sample pre-
paration procedure previous to its injection into the liquid chroma-
tography–tandem mass spectrometry (LC–MS/MS) system to monitor
levels of adrenaline, noradrenaline, glutamic acid, γ-aminobutyric
acid, dopamine, 5-hydroxytryptamine, 5-hydroxyindole acetic acid,
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A. Wojnicz et al. / Data in Brief 7 (2016) 714–720 715method validation assays (such as calibration curve, lower limit of
quantiﬁcation, precision and accuracy intra- and inter-day, selectivity,
extraction recovery and matrix effect, stability, and carry-over effect)
according to the United States Food and Drug Administration and
European Medicine Agency to measure in one step different neuro-
transmitters and their metabolites. The data supplied in this article is
related to the research study entitled: “Simultaneous determination of
8 neurotransmitters and their metabolite levels in rat brain using
liquid chromatography in tandem with mass spectrometry: applica-
tion to the murine Nrf2 model of depression” (Wojnicz et al. 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Analytical Chemistry
ore speciﬁc sub-
ject areaBiochemistry, neurotransmittersype of data Table, ﬁgure
ow data was
acquiredMS/MS was acquired in a triple quadrupoleata format Raw mass spectra data, analyzed data and excel ﬁles (xls)
xperimental
factorsBrain samples were homogenized in ice-cold 1.89% formic acid in water and
centrifuged. Acetonitrile with 1% formic acid was added to the supernatant with
internal standard for protein precipitation (4:1, v/v) and centrifuged. The
supernatant was evaporated and reconstituted with mobile phase before
injection.xperimental
featuresRat brain was homogenized and protein precipitation as sample preparation was
performed. Neurotransmitters and metabolites were determined by liquid
chromatography-tandem mass spectrometry. Method validation was carried out
according to the regulatory agencies.ata source
locationMadrid, Spainata accessibility Data is within this articleD
Value of the data
 Dataset of product ion mass spectra of 8 neurotransmitters and metabolites using a triple
quadrupole.
 The data presented the sample preparation procedure performed to clean up the rat brain samples.
 Dataset of method validation assays according to the recommendations of United States Food and
Drug Administration and European Medicine Agency.
 Rapid quantiﬁcation of neurotransmitters and metabolites using this method is of potential use to
diagnose neurological diseases.1. Data
The following dataset includes 2 ﬁgures and 1 table that support the sample preparation and method
validation assays required to monitor levels of adrenaline (AD), noradrenaline (NA), glutamic acid (Glu),
γ-aminobutyric acid (GABA), dopamine (DA), 5-hydroxytryptamine (5-HT), 5-hydroxyindole acetic acid
A. Wojnicz et al. / Data in Brief 7 (2016) 714–720716(5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) by liquid chromatography–tandem mass
spectrometry (LC–MS/MS) in rat brain samples.2. Experimental design, materials and methods
2.1. Chromatographic and mass spectrometry conditions
All the chromatographic and mass spectrometry conditions are related to [1]. Here, we describe
raw dataset of product ion mass spectra. Fig. 1 shows the mass spectra of the precursor ion and the
product ion that were optimized and the fragmentation pattern for each analyte. The integration peak
area corresponding to the transition mass to charge (m/z) of each analyte was quantiﬁed using Mass
Hunter Workstation Quantitative Analysis software (Agilent Technologies, Santa Clara, Unites States).
2.2. Sample preparation
The data described here has been carried out in accordance with Ethics Committee of the School of
Medicine-Universidad Autónoma de Madrid- and international guidelines of animal care and welfare
for the experiments involving animals. Whole brain was obtained from adult male Sprague-Dawley
rats (250–300 g). The rats were sacriﬁced by decapitation and the brain tissue was frozen immedi-
ately at –80°C. The brain samples were weighed and homogenized using Polytron PT 1200C (Kine-
matica, Lucerne, Switzerland) in ice-cold 1.89% formic acid in water at a concentration of 10 mL/g
tissue and centrifuged at 14,000 rpm and 4°C for 40 min.AD (184.2  > 166.2) NA (170.2 > 107.1)
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Fig. 1. Product ion spectrums and chemical structures with the fragmentation pattern of neurotransmitters and their meta-
bolites. The precursor ion and the product ions are shown in the ﬁgure. The quantiﬁer multiple-reaction monitoring transition
is indicated for each compound. The chemical structure with the fragmentation pattern is shown. All chromatograms have been
normalized to the largest peak. Abbreviations: AD: adrenaline; NA: noradrenaline; Glu: glutamic acid; GABA: γ-amino butyric
acid; DA: dopamine; 5-HT: serotonin; MHPG: 3-methoxy-4-hydroxyphenylglycol; 5-HIAA: 5-hydroxyindoleacetic acid; IS:
internal standard.
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Fig. 2. Sketch of sample preparation procedure.
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concentration of 500 ng/mL in a 9:1 proportion (v/v). ACN with 1% formic acid was added to the
supernatant with IS for protein precipitation (PPT) in a 4:1 proportion (v/v) and centrifuged at
14,000 rpm and 4°C for 5 min. The supernatant was then evaporated to dryness using a concentrator
(5301, Eppendorf, Germany) at 45°C for 1 h and 15 min. Finally, the dry residue was reconstituted
with the mobile phase (0.2% formic acid in water/ACN [95:5, v/v]) with the same volume obtained
before PPT. Samples were transferred to vials to be injected directly into the LC–MS/MS (Fig. 2).
Owing to the high concentrations of the endogenous analytes of GABA, Glu, DA, and 5-HT, the
brain homogenate supernatant was diluted 100 times before PPT for the validation assays.
2.3. Assay validation procedures
The datasets of method validation assays described here are according to FDA [2] and EMA [3]
recommendations. Calibration standards and quality controls (QCs) were prepare from independent
dilutions of each stock solution and spiked in the brain homogenate. The concentrations of analytes in
the QC solutions were calculated by using calibration curves on every validation day. Because of the
presence of endogenous analytes in brain samples, the response of the blank matrix sample should be
subtracted from each calibration point and QC.
2.3.1. Calibration curve and lower limit of quantitation (LLOQ)
Quantitative analysis of neurotransmitters and their metabolites was performed in rat brain
homogenate using isoprenaline as the IS (500 ng/mL). Eight calibration standards in concentration
ranges of 0.25–200, 0.5–200, 250–20,000, 250–20,000, 0.25–200, 10–3000, 1–50, and 1–50 ng/mL
were used for validation in the case of AD, NA, Glu, GABA, DA, 5-HT, 5-HIAA, and MHPG, respectively.
A weighted linear or polynomial regression model adjusted for least squares was used to calculate the
equation relating the area ratio of analyte versus IS to the concentration of analyte in the calibration
Table 1
Concentration ranges, weighted regression models adjusted, correlation coefﬁcient, and lower limits of quantiﬁcation for each
compound.
Compound Equation Linear range Correlation LLOQ
(ng/mL) Coefﬁcient
mean7SD
(ng/mL)
AD Polynomial 3rd
order
0.25–185 1.000070.0000 0.25
NA Linear* 0.5–200 0.999670.0004 0.50
Glu Polynomial 3rd
order
250–20,000 0.999970.0001 250
GABA Polynomial 3rd
order
250–20,000 1.000070.0000 250
DA Polynomial 3rd
order
0.25–200 1.000070.0000 0.25
5-HT Linear* 10–3000 0.994870.0040 10
MHPG Polynomial 3rd
order
1–50 0.999370.0002 1
5-HIAA Linear 1–50 0.993670.0023 1
Abbreviations: AD: adrenaline; NA: noradrenaline; Glu: glutamic acid; GABA: γ-amino butyric acid; DA: dopamine; 5-HT:
serotonin; MHPG: 3-methoxy-4-hydroxyphenylglycol; 5-HIAA: 5-hydroxyindoleacetic acid.
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curve was chosen to cover the range of the relevant endogenous concentrations expected in most rat
brain tissue. At least 6 of 8 calibration standards should be less than 15% of the coefﬁcient of variation
(CV) in order to validate the calibration curve. For each point of the calibration curve, the error of
accuracy and CV should be less than 15% for all calibration standards, except for the LLOQ, which was
less than 20%. The LLOQ response of the analyte should be at least 5 times higher than the blank
response.
2.3.2. Precision and accuracy
Critical factors for measurement of the reproducibility of the assay are precision, which is deﬁned
as the repeatability of the assay, and accuracy, which is the closeness to the true value of the value
obtained by the method. The precision and accuracy of the dataset were assessed by analyzing
5 replicates per 4 concentration levels in a single analytical run, namely, LLOQ and low, medium, and
high QCs, which covered the calibration curve range. The intra-day precision and accuracy were
evaluated by analyzing 5 replicates of each QC level on a single day. The inter-day variation was
evaluated by injecting each QC sample in 5 replicates over 3 analytical runs from at least
3 different days.
Precision is expressed as the CV (%). Accuracy was deﬁned as the percentage difference between
the theoretical and the measured value according to the following equation:
Accuracy %ð Þ ¼ concentrationmeasured–concentrationtheoretical½ 
concentrationtheoretical½   100%
To validate precision and accuracy, the error must be less than 15% for all QCs except the LLOQ,
which must be within 20% of the true value.
2.3.3. Selectivity
The selectivity of the method is the ability to differentiate the analytes of interest and IS from
endogenous or other components in the matrix. Selectivity was tested in 6 different lots of rat brain
homogenates with IS (zero matrix sample) or without IS (blank matrix sample), which were then
individually analyzed for interference. Absence of interfering components should be accepted where
the response is less than 5 times (20%) the LLOQ for the analyte and 20 times (5%) for the IS. Because
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sample subtraction with blank sample response (mobile phase).
2.3.4. Extraction recovery and matrix effect
The relative recovery to its IS is evaluated as the ratio of compound concentrations in brain
homogenate following PPT to the same concentration dissolved directly in reconstitution solution.
Three repetitions of low and high QCs for neurotransmitters and their metabolites were analyzed in
3 different batches of rat brain homogenates. Therefore, recovery refers to the efﬁciency of extraction
of an analysis method. Recovery of the analyte need not be 100% to be adequate, but the extent of
recovery of QC samples should be precise, reliable, and reproducible.
The relative matrix effect of rat brain homogenate was measured through the addition of a known
concentration of analyte with its IS to a rat brain homogenate that had undergone PPT. This response
is compared with the addition of the same amount of analyte and IS to a ﬁnal reconstitution solution.
This time, 6 repetitions per concentration level were analyzed in 6 different lots of rat brain homo-
genate at low and high QCs for neurotransmitters and their metabolites. To validate the matrix effect,
the CV should not be greater than 15% for all the QCs.
2.3.5. Stability
We evaluated the stability assays at 2 concentration levels (low and high QCs), as follows: (1) after
24 h at 23°C in the autosampler; (2) after 24 h at 4°C in the fridge; (3) after 3 cycles of freeze–thaw in
the freezer at –80°C. For all assays, 3 replicates of low and high QCs for all the analytes were per-
formed and analyzed according to the criteria of the FDA and the EMA. The stability was considered
acceptable if it was within a CV of less than 15% for all the QCs used. In this way, we guaranteed
sample preparation, the analytical process, and the storage conditions.
2.3.6. Carry-over
Carry-over is the presence of an analyte signal in a blank sample after the analysis of samples with
a high analyte concentration. Transfer should be minimal. Carry-over should be assessed by injecting
blank samples after a high concentration sample or calibration standard at the upper limit of
quantiﬁcation. Carry-over in the blank sample following the high concentration standard should not
exceed 20% of the LLOQ. Between injections, the needle was washed with water and methanol (50:50)
solution to prevent carry-over.Acknowledgments
The authors wish to thank to Instituto-Fundación Teóﬁlo Hernando for its continued ﬁnancial
support. We also wish to recognize Esteban Paniagua (SYMTA, Madrid, Spain) for their technical
assistance. This dataset was also supported by “FIS No. CA12/00122” to ARN, Minstry of Education,
Culture and Sport “FPU12/02220” to AW and the Ministry of Economy and Competitiveness “SAF
2012-32223” to MGL.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.03.025.References
[1] A. Wojnicz, J. Avendano Ortiz, A.I. Casas, A.E. Freitas, G.L. M, A. Ruiz-Nuno, Simultaneous determination of 8 neuro-
transmitters and their metabolite levels in rat brain using liquid chromatography in tandem with mass spectrometry:
application to the murine Nrf2 model of depression, Clin. Chim. Acta 453 (2016) 174–181.
A. Wojnicz et al. / Data in Brief 7 (2016) 714–720720[2] F.D.A., Homepage, Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/4252fnl.htm
(last access, July 27, 2011), 2001.
[3] E.M.A., Homepage, Guideline on bioanalytical method validation, EMEA/CHMP/EWP/192217/2009, http://www.ema.
europa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/2011/08/WC500109686.pdf, 2011.
